Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has given notice that its Annual General Meeting will be held at 10:00 am on 30 November 2020 at the offices of Zeus Capital, 10 Old Burlington Street, London, W1S 3AG.
The Company’s Annual Report and Accounts for the year ended 31 May 2020 and the Notice of Annual General Meeting have been sent to shareholders and can also be viewed on the “Investors” section of the Company’s website at www.oncimmune.com.
As a result of the current UK Government guidance on social distancing and prohibiting public gathering over certain numbers, the Company has taken the decision that this year unfortunately it will not be possible for shareholders to attend the AGM in person. The AGM will therefore be primarily functional in formation with only a small number of Directors and/or other employee shareholders attending in person.
Details on how shareholders can vote by proxy are set out in the Notice of Annual General Meeting. The Company therefore requests that shareholders appoint the Chairman of the meeting as a proxy and provide their voting responses in advance of the AGM.
In order to facilitate engagement with shareholders, shareholders can submit questions to the Directors ahead of the AGM by email to agm2020@oncimmune.com. The Directors will endeavour to respond to appropriately raised questions in a timely manner.
